Cerebral venous thrombosis in Argentina: clinical presentation, predisposing factors, outcomes and literature review
- PMID: 32912503
- DOI: 10.1016/j.jstrokecerebrovasdis.2020.105145
Cerebral venous thrombosis in Argentina: clinical presentation, predisposing factors, outcomes and literature review
Abstract
Background: Cerebral venous thrombosis (CVT) is a rare medical condition that primarily affects young adults. The clinical spectrum is broad and its recognition remains a challenge for clinicians. Limited information is available on CVT in Argentina. Our goal was to report the results of the first National registry on CVT in Argentina and to compare clinical presentation, predisposing factors and outcomes with other international registries.
Material and method: The Argentinian National Registry on CVT (ANR-CVT) is a multicenter retrospective cohort study comprising patients aged 18 and older with a diagnosis of CVT from January 2015 to January 2019. We evaluated demographics, predisposing factors, clinical presentation, and radiological characteristics (e.g. number of involved sinuses, venous infarction or hemorrhage on CT and MRI scans at admission), therapeutic interventions and functional outcomes at discharge and at 90 days. Our results were compared to a literature review of CVT registries.
Results: Overall, one hundred and sixty-two patients met the inclusion criteria. The mean age was 42 (±17) years; 72% were women. Seventy percent of patients were younger than 50 years. The most common presenting symptom was headache (82%). The transverse sinus was the most common site of thrombosis (70%) followed by the sigmoid sinus (46%). The main predisposing factor in women was contraceptive use (44%), 3% of the events occurred during pregnancy and 9% during the puerperium. Participants 50 years and older had a higher frequency on malignancy related (7.5% vs. 30%, p = 0.0001) and infections (2% vs. 11%, p = 0.001). The modified Rankin Scale (mRS) ≤2 at discharge was 81% and the rate of mortality at discharge was 4%. At 90 days, the mRS≤2 was 93%. When the ANR-CVT was compared with larger registries from Europe and Asia, the prevalence of cancer among patients with CVT was two to five-fold higher (15% vs. 7% and 3%, respectively; p = 0.002 and p < 0.001). Anticoagulation rates at discharge were also higher (94%) compared to registries from Asia (ASCVT - 68%) or Turkey (VENOST - 67%).
Conclusion: Participants in the first ANR-CVT had a low mortality and disability at 90 days. Clinical and radiological characteristics were similar to CVT from other international registries with a higher prevalence of cancer. There was a high variability in treatment adherence to guidelines as reflected by anticoagulation rates (range 54.5%-100%) at discharge.
Keywords: Argentine; cerebral veins; cerebral venous sinus thrombosis; cerebrovascular disease; outcome; registry; stroke.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest All authors certify that they have no affiliations with or involvement in any organization or entity with any financial or nonfinancial interest in the subject matter or materials discussed in this manuscript.
Similar articles
-
Asian Study of Cerebral Venous Thrombosis.J Stroke Cerebrovasc Dis. 2019 Oct;28(10):104247. doi: 10.1016/j.jstrokecerebrovasdis.2019.06.005. Epub 2019 Jul 24. J Stroke Cerebrovasc Dis. 2019. PMID: 31350167
-
Cerebral venous thrombosis: clinical features, risk factors, and long-term outcome in a Tunisian cohort.J Stroke Cerebrovasc Dis. 2014 Jul;23(6):1291-5. doi: 10.1016/j.jstrokecerebrovasdis.2013.10.025. Epub 2014 Jan 22. J Stroke Cerebrovasc Dis. 2014. PMID: 24462460
-
Mortality in cerebral venous thrombosis: results from the national inpatient sample database.Cerebrovasc Dis. 2013;35(1):40-4. doi: 10.1159/000343653. Epub 2013 Feb 14. Cerebrovasc Dis. 2013. PMID: 23428995
-
Apixaban for the treatment of cerebral venous thrombosis: A case series.J Neurol Sci. 2017 Oct 15;381:318-320. doi: 10.1016/j.jns.2017.09.007. Epub 2017 Sep 6. J Neurol Sci. 2017. PMID: 28991706 Review.
-
Cerebral venous thrombosis.Nat Rev Neurol. 2017 Sep;13(9):555-565. doi: 10.1038/nrneurol.2017.104. Epub 2017 Aug 18. Nat Rev Neurol. 2017. PMID: 28820187 Review.
Cited by
-
Cerebral Venous Sinus Thrombosis Triggered by Severe Dehydration.Cureus. 2024 Nov 28;16(11):e74654. doi: 10.7759/cureus.74654. eCollection 2024 Nov. Cureus. 2024. PMID: 39735097 Free PMC article.
-
The genetic risk factors for cerebral venous thrombosis: a case-control study in a Chinese national comprehensive hospital.Thromb J. 2024 Jun 17;22(1):50. doi: 10.1186/s12959-024-00621-8. Thromb J. 2024. PMID: 38886735 Free PMC article.
-
Venous stroke-a stroke subtype that should not be ignored.Front Neurol. 2022 Oct 6;13:1019671. doi: 10.3389/fneur.2022.1019671. eCollection 2022. Front Neurol. 2022. PMID: 36277910 Free PMC article. Review.
-
Cavernous Sinus Thrombosis Linked to COVID-19 Infection: a Case Report.SN Compr Clin Med. 2023;5(1):111. doi: 10.1007/s42399-023-01450-y. Epub 2023 Mar 22. SN Compr Clin Med. 2023. PMID: 36970581 Free PMC article.
-
SWI brush sign of cerebral parenchymal veins in central nervous system diseases.Jpn J Radiol. 2025 May;43(5):726-735. doi: 10.1007/s11604-024-01723-z. Epub 2024 Dec 28. Jpn J Radiol. 2025. PMID: 39730932 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous